Palantir: $150 Price Key For Bulls - Risk Of Major Bear Slide Rising

Palantir Technologies Inc. faces steep downside risk as extreme valuation meets weakening signals and insider selling. Click ...

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...

Biohaven Ltd.: Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan ...

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE and next-generation, highly selective ...

Johnson & Johnson: RYBREVANT (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...